Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $26.06 up 2.64% from its previous closing price of $25.39. In other words, the price has increased by $2.64 from its previous closing price. On the day, 0.8 million shares were traded. RNA stock price reached its highest trading level at $26.1 during the session, while it also had its lowest trading level at $25.0454.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 03, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On March 14, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $60.
Evercore ISI Upgraded its In-line to Outperform on May 22, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 07 ’24 when Boyce Sarah sold 28,000 shares for $25.54 per share. The transaction valued at 715,050 led to the insider holds 112,117 shares of the business.
LEVIN ARTHUR A sold 5,000 shares of RNA for $114,123 on Apr 19 ’24. The Director now owns 14,830 shares after completing the transaction at $22.82 per share. On Apr 03 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 20,000 shares for $27.11 each. As a result, the insider received 542,214 and left with 253,872 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 2491982336 and an Enterprise Value of 1438578432. For the stock, the TTM Price-to-Sale (P/S) ratio is 260.65 while its Price-to-Book (P/B) ratio in mrq is 4.13. Its current Enterprise Value per Revenue stands at 150.479 whereas that against EBITDA is -6.161.
Stock Price History:
The Beta on a monthly basis for RNA is 0.79, which has changed by 1.1963668 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $27.66, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 10.93%, while the 200-Day Moving Average is calculated to be 113.59%.
Shares Statistics:
For the past three months, RNA has traded an average of 1.16M shares per day and 828990 over the past ten days. A total of 95.62M shares are outstanding, with a floating share count of 85.60M. Insiders hold about 10.48% of the company’s shares, while institutions hold 84.06% stake in the company. Shares short for RNA as of 1713139200 were 10661773 with a Short Ratio of 9.21, compared to 1710460800 on 8616024. Therefore, it implies a Short% of Shares Outstanding of 10661773 and a Short% of Float of 14.59.
Earnings Estimates
The current assessment of Avidity Biosciences Inc (RNA) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.95, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.67 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.71 and -$4.19 for the fiscal current year, implying an average EPS of -$3.2. EPS for the following year is -$3.53, with 7.0 analysts recommending between -$2.76 and -$4.65.
